The most common activating EGFR mutations in NSCLC are exon 19 deletions (>50 %) followed by the p.L858R point mutation in exon 21 (∼40 %), both of which are associated with a positive response to EGFR-TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.